Gustave Roussy

This research focuses on musculoskeletal symptoms caused by aromatase inhibitor therapy in early‑stage hormone‑receptor‑positive breast cancer, testing a novel oral cannabidiol solution to alleviate joint pain.

• Double‑blind, placebo‑controlled design
• Pain assessment with the Brief Pain Inventory short form
• Target population: early breast cancer patients receiving adjuvant endocrine therapy
• Evaluation of safety and efficacy over a 12‑week treatment period

Conducted at Gustave Roussy in Chevilly‑Larue, France, the study aims to improve quality of life for patients on oral anticancer regimens.

This program assesses a reinforced multi‑professional pathway that unites oncologists, geriatricians, pharmacists and pharmacologists to lower severe toxicities in patients aged 70 + receiving oral cancer therapy.

• Coordination of oncogeriatric, pharmaceutical and pharmacological follow‑up
• Monitoring of grade ≥3 non‑hematologic and grade ≥4 hematologic adverse events
• Comparison with usual care over a maximum of 24 months
• Inclusion of diverse tumor cohorts treated with oral agents

The trial at Gustave Roussy addresses the safety challenges of treating elderly cancer patients while maintaining therapeutic effectiveness.